Neuropeptide research
VIP Dosage, Protocol & Research Guide
Reconstitution calculator
Calculator example, not a recommended amount
- Concentration
- 2.5 mg/mL
- Volume to draw
- 0.1 mL
- Units on a U-100 syringe
- 10 units
Properties
- CAS
- Not yet recorded
- Molecular weight
- Not yet recorded
- Formula
- Not yet recorded
- Sequence
- Not yet recorded
- Aliases
- Vasoactive intestinal peptide, Aviptadil
- Vial sizes (mg)
- 5
Storage notes
- Lyophilized
- Not yet recorded from a cited source
- Reconstituted stability (days)
- Not yet recorded from a cited source
Side effects, contraindications and regulatory status
Reported side effects
- Intravenous aviptadil (synthetic VIP), 3 days, COVID-19 respiratory failure (TESICO, 231 aviptadil, 230 placebo): death, serious or grade 3-4 adverse events, organ failure or serious infection to day 5 in 146 (63%) vs 129 (56%), OR 1.40 (95% CI 0.94-2.08).[2] Human trial
- Aviptadil (synthetic VIP) given intravenously for 3 days in 196 patients with COVID-19 respiratory failure: the authors report an absence of drug-related serious adverse events (Crit Care Med 2022; sponsor-affiliated authors).[3] Human trial
- Different product: Invicorp (aviptadil 25 mcg + phentolamine 2 mg, intracavernosal). German drug profile: about 10% had side effects, most often a feeling of heat; headache, dizziness, tachycardia, palpitations, injection-site bleeding or bruising; prolonged erection and penile fibrosis can occur.[1] Observational
Cautions from reviews and trials
- Review cautions (trade-press drug profile of a different product, not a label): Invicorp (aviptadil + phentolamine, intracavernosal) lists leukemia, multiple myeloma, sickle cell disease or trait, penile deformation or prosthesis, priapism risk, anticoagulants and hypersensitivity.[1] Observational
Regulatory status
Invicorp (aviptadil 25 mcg + phentolamine 2 mg, intracavernosal; not VIP alone) is listed as marketed in Germany since 03/2022 in a trade-press profile; US status not checked. Checked 2026-10-20.[1] Source
Report any adverse reaction to a qualified healthcare professional.
What the research says
Summaries of the cited studies, each with its evidence grade.
TESICO randomised placebo-controlled trial (Lancet Respir Med 2023) in COVID-19 hypoxaemic respiratory failure[2]
TESICO randomised placebo-controlled trial (Lancet Respir Med 2023) in COVID-19 hypoxaemic respiratory failure: intravenous aviptadil as a daily 12-h infusion for 3 days targeting 600, 1200 and 1800 pmol/kg on days 1, 2 and 3 (NCT04843761)
Randomised placebo-controlled trial (Crit Care Med 2022) in 196 patients with COVID-19 respiratory failure[3]
Randomised placebo-controlled trial (Crit Care Med 2022) in 196 patients with COVID-19 respiratory failure: aviptadil (synthetic VIP) intravenously for 3 days, randomised 2:1 to placebo; dose not printed in the abstract
Frequently asked questions
What is the regulatory status of VIP?
Invicorp (aviptadil 25 mcg + phentolamine 2 mg, intracavernosal; not VIP alone) is listed as marketed in Germany since 03/2022 in a trade-press profile; US status not checked. Checked 2026-10-20.
Compound facts
What is the molecular weight of VIP?
What is the CAS number of VIP?
How is VIP stored in the laboratory?
References
Numbered sources used on this page. Markers in the text link here.
- pharmazeutische-zeitung.de Observational
- TESICO randomised placebo-controlled trial (Lancet Respir Med 2023) in COVID-19 hypoxaemic respiratory failure pubmed.ncbi.nlm.nih.gov Human trial
- Randomised placebo-controlled trial (Crit Care Med 2022) in 196 patients with COVID-19 respiratory failure pubmed.ncbi.nlm.nih.gov Human trial